Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein

Scandinavian Cardiovascular Journal

Volumn 47, Issue 1, 2013, Pages 20-27

  Berthold, Heiner K ^a   Berneis, Kaspar ^b   Mantzoros, Christos S ^c   Krone, Wilhelm ^d   Gouni Berthold, Ioanna ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Anti inflammatory; Effects; Ezetimibe; High sensitivity C reactive protein; Interleukin 6; Pleiotropic effects; Simvastatin; Statins

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; EZETIMIBE; INTERLEUKIN 6; LEPTIN; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; SIMVASTATIN; THYROTROPIN; THYROXINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY FAT; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MOLECULAR WEIGHT; NEUTROPHIL COUNT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SIMVASTATIN; TIME FACTORS; YOUNG ADULT;

EID: 84872516561     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2012.734635     Document Type: Article

References (30)

1. Liao JK, L aufs U. P leiotropic effects of statins. A nnu Rev Pharmacol Toxicol. 2005 ; 45: 89-118.
2. Ridker PM, H ennekens CH, B uring JE, R ifai N. C -reactive protein and other markers of infl ammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 ; 342: 836-43.
3. Weinhold B, R uther U. I nterleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J. 1997 ; 327: 425-9.
4. Zhang YX, C liff WJ, S choefl GI, H iggins G. C oronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999 ; 145: 375-9.
5. Plenge JK, H ernandez T L, W eil KM, P oirier P, Grunwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002 ; 106: 1447-52.
6. Strandberg T E, V anhanen H, T ikkanen MJ. A ssociations between change in C-reactive protein and serum lipids during statin treatment. Ann Med. 2000 ; 32: 579-83.
7. Berthold HK, N aini A, D i Mauro S, H allikainen M, Gylling H, Krone W, Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: A randomised trial. Drug Saf. 2006 ; 29: 703-12.
8. Pearson TA, B allantyne CM, V eltri E, S hah A, B ird S, L in J, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009 ; 103: 369-74.
9. Berneis K, R izzo M, B erthold HK, S pinas G A, K rone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: A randomized trial. Eur Heart J. 2010 ; 31: 1633-9.
10. Gouni-Ber 10. thold I, B erthold H K, G ylling H, H allikainen M, Giannakidou E, Stier S, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: A randomized trial in healthy men. Atherosclerosis. 2008 ; 198: 198-207.
11. Gouni-Berthold I, B erthold H K, C hamberland J P, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf). 2008 ; 68: 536-41.
12. Krysiak R, O kopien B. T he effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol. 2011 ; 57: 505-12.
13. Devaraj S, C han E, J ialal I. D irect demonstration of an antiinfl ammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006 ; 91: 4489-96.
14. Lee S H, K ang S M, P ark S, J ang Y, C hung N, C hoi D. The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A 2. Clin Cardiol. 2011 ; 34: 108-12.
15. Undas A, M achnik A, P otaczek D P, W ypasek E, Z mudka K, Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fi brinolysis in patients after acute coronary events. J Cardiovasc Pharmacol. 2011 ; 58: 167-72.
16. Hoppe C, K uypers F, L arkin S, H agar W, V ichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011 ; 153: 655-63.
17. K ater AL, B atista M C, F erreira S R. S ynergistic effect of simvastatin and ezetimibe on lipid and pro-infl ammatory profi les in pre-diabetic subjects. Diabetol Metab Syndr. 2010; 2: 34.
18. Nozue T, M ichishita I, M izuguchi I. E ffects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb. 2010 ; 17: 37-44.
19. Yagi S, Akaike M, Aihara K, Iwase T, Ishikawa K, Yoshida S, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb. 2010 ; 17: 173-80.
20. Piorkowski M, F ischer S, S tellbaum C, J aster M, M artus P, Morguet AJ, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is suffi cient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007 ; 49: 1035-42.
21. Rudofsky G, R eismann P, G roener JB, D juric Z, F leming T, Metzner C, et al. Identical LDL-cholesterol lowering but non-identical effects on NF-kappaB activity: high dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis. 2012 ; 223: 190-6.
22. Berneis K, R izzo M, E vans J, R ini GB, S pinas GA, Goedecke JH. Interleukin-18 levels are associated with low-density lipoproteins size. Eur J Clin Invest. 2010 ; 40: 54-5.
23. Ballantyne CM, H ouri J, N otarbartolo A, M elani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation. 2003 ; 107: 2409-15.
24. Pesaro A E, Serrano CV Jr., Fernandes JL, Cavalcanti AB, Campos AH, Martins HS, et al. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2011; 158 :400-404.
25. Dawson JA, Choke E, Loftus IM, Cockerill GW, Thompson MM. A randomised placebo-controlled doubleblind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and infl ammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2011 ; 41: 28-35.
26. Emerging Risk Factors Collaboration, K aptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet. 2010; 375: 132-40.
27. Heart Protection Study Collaborative Group, Jonathan E, Derrick B, Emma L, Sarah P, John D, Jane A, Rory C. C-reactive protein concentration and the vascular benefi ts of statin therapy: An analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011 ; 377: 469-76.
28. Wijnstok NJ, T wisk JW, - oung IS, W oodside JV, M cFarlane C, McEneny J, et al. Infl ammation markers are associated with cardiovascular diseases risk in adolescents: the Young Hearts project 2000. J Adolesc Health. 2010 ; 47: 346-51.
29. Seedorf U, E ngel T, L ueken A, B ode G, L orkowski S, Assmann G. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun. 2004 ; 320: 1337-41.
30. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009 ; 373: 1175-82.